Consensus Fennec Pharmaceuticals Inc. Toronto S.E.

Stocks

FRX

CA31447P1009

Pharmaceuticals

Delayed Toronto S.E. 10:25:44 2026-09-21 EDT			5-day change	1st Jan Change
15.00 ^CAD	0.00%		-12.28%	+41.51%

09-17	Fennec Pharmaceuticals Announces Oral Presentation Of Detailed Results From Investigator-Initiated Phase 2 STS-J01 Clinical Study Of Pedmark In Japan At SIOP 2026	CI
08-12	B. Riley Adjusts Fennec Pharmaceuticals Price Target to $18 From $16, Maintains Buy Rating	MT

bb7.4tIkPNagWtcUP5lG9vPHVMldk2EiCOVtdo6DRAlZupU.gJt-DobyF7F-bNJ_n6S0H44c3wNXa7IiJcazPWcTwvnbolR3uZFsvnNN0A~e4d099fc45a5117048b84f8707e44370

Analysts' recommendations: Fennec Pharmaceuticals Inc.

08-12	B. Riley Adjusts Fennec Pharmaceuticals Price Target to $18 From $16, Maintains Buy Rating	MT
08-11	Wedbush Adjusts Fennec Pharmaceuticals PT to $16 From $13, Maintains Outperform Rating	MT
04-16	Wedbush Refines Fennec Pharmaceuticals Estimates Ahead of Q1 Earnings	MT
03-24	Wedbush Maintains Outperform, US$13.00 Price Target on Fennec After Inline Q4	MT
03-17	B Riley Reaffirms Fennec's Buy Rating, US$16.00 Price Target After Cipla Settlement	MT
02-20	Wedbush "Encouraged" by Study on Fennec's Pedmark's Impact on Adults Treated With Cisplatin	MT
02-12	B. Riley Initiates Fennec Pharmaceuticals at Buy With CA$21.69 Price Target	MT
01-09	Piper Sandler Initiates Fennec Pharmaceuticals at Overweight	MT
11-14	Wedbush Says Fennec's Q3 Revenue Beats Estimates, Backs Outperform Rating	MT
11-13	Fennec Pharmaceuticals Q3 product sales rise	RE
25-10-14	Wedbush Maintains Outperform, US$13 Price Target on Fennec Pharmaceuticals	MT
24-08-13	Wedbush Adjusts Fennec Pharmaceuticals' PT to $14 From $16, Keeps Outperform Rating	MT
24-05-15	HC Wainwright Adjusts Fennec Pharmaceuticals Price Target to $15 From $18, Maintains Buy Rating	MT
24-04-04	HC Wainwright Raises Fennec Pharmaceuticals Price Target to $18 From $17, Maintains Buy Rating	MT
23-08-04	HC Wainwright Adjusts Price Target on Fennec Pharmaceuticals to $17 From $18, Maintains Buy Rating	MT
23-04-06	Cantor Fitzgerald Adjusts Fennec Pharmaceuticals' Price Target to $16 From $12	MT
23-03-30	Wedbush Adjusts Fennec Pharmaceuticals Price Target to $16 From $17, Maintains Outperform Rating	MT
23-01-25	Wedbush Lowers Fennec Pharmaceuticals' Price Target to $17 From $19, Maintains Outperform Rating	MT
22-11-22	Cantor Fitzgerald Upgrades Fennec Pharmaceuticals to Overweight From Neutral, Adjusts Price Target to $12 From $9	MT
22-10-20	HC Wainwright Adjusts Fennec Pharmaceuticals' Price Target to $18 From $14, Keeps Buy Rating	MT
22-09-29	Maxim Adjusts Fennec Pharmaceuticals' Price Target to $15 from $10, Maintains Buy	MT
22-09-26	Wedbush Adjusts Fennec Pharmaceuticals Price Target to $19 From $11, Maintains Outperform Rating	MT
22-09-07	Capital One Starts Fennec Pharmaceuticals at Overweight With $11 Price Target	MT
22-08-08	Craig-Hallum Assumes Fennec Pharmaceuticals at Buy With $14 Price Target	MT
22-05-12	Wedbush Maintains Outperform, Raises Fennec Pharmaceuticals' TP to US$11	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ELI LILLY AND COMPANY					+13.78%
	JOHNSON & JOHNSON					+3.13%
	ABBVIE INC.					+5.34%
	ROCHE HOLDING AG					+2.89%
	NOVARTIS AG					+7.94%
	ASTRAZENECA PLC					+25.8%
	AMGEN INC.					-1.39%
	NOVO NORDISK A/S					+18.79%
	GILEAD SCIENCES, INC.					+5.04%
	Average					+9.04%
	Weighted average by Cap.					+9.04%